$6
Profound Medical
Performance
Dividends
1W
1M
YTD
1Y
3Y
22/36
Growth
Score
8/36
Dividend
Score
Valuation
PE Ratio
-5.7
PS Ratio
16.19
RSI
-
3
PEG Ratio
0.5
0
PRG Ratio
0
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
123.02%
2
Gross Margin
66.9%
3
Current Ratio
11.31
Return on Assets
-53.14%
Return on Equity
-71.27%
Return on inv. Capital
-37.76%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 10.68M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -27.82M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 7.04M
2018
2019
2020
2021
2022
2023
2024
6
Events
PROF
Profound Medical
in 288 days
after market close
Earnings per Share is expected with - and revenue with - .
PROF
Profound Medical
in 225 days
after market close
Earnings per Share is expected with - and revenue with - .
PROF
Profound Medical
in 106 days
after market close
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Medical - Devices
IPO Date
29.10.2019
MaketCap
184.46M
Country
CA
CEO
Dr. Arun Swarup Menawat MBA, Ph.D.
Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Updated 26.06.2025